This activity focuses on dutasteride, a medication for managing benign prostatic hyperplasia (BPH). As an irreversible inhibitor of both type I and type II 5α-reductase, dutasteride plays a pivotal role in impeding the enzymatic conversion of testosterone to 5-α-dihydrotestosterone. The pharmacodynamic and pharmacokinetic aspects of dutasteride will be discussed, in addition to the approved and off-label indications and the mechanism of action. This knowledge equips healthcare professionals to identify potential interactions with other drugs, diseases, and dietary factors. The activity also discusses adverse effects, contraindications, and toxicity profiles, emphasizing considerations for special patient populations, including those with compromised renal or hepatic function. The overarching objective is to empower the healthcare team to optimize patient outcomes in the context of BPH treatment.
- Provider:StatPearls, LLC
- Activity Link: https://www.statpearls.com/ArticleLibrary/viewarticle/161479
- Start Date: 2024-12-01 06:00:00
- End Date: 2024-12-01 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABS - 1.0 Point; Credit Type(s): Accredited CME (ABS)
ABPATH - 1.0 Point; Credit Type(s): Lifelong Learning (ABPATH)
ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
ABS - 1.0 Point; Credit Type(s): Self-Assessment (ABS) - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: All Practice Areas (e.g. ethics), General Surgery, Geriatric Medicine, Internal Medicine